Assertio Therapeutics Stock Investor Sentiment
| ASRT Stock | USD 0.96 0.03 3.23% |
Slightly above 64% of all Assertio Therapeutics' private investors are looking to take a long position. The analysis of overall sentiment of trading Assertio Therapeutics stock suggests that some investors are interested at this time. Assertio Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Assertio Therapeutics' earnings reports, geopolitical events, and overall market trends.
Assertio |
Assertio Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Assertio Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Assertio Therapeutics that are available to investors today. That information is available publicly through Assertio media outlets and privately through word of mouth or via Assertio internal channels. However, regardless of the origin, that massive amount of Assertio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Assertio Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Assertio Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Assertio Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Assertio Therapeutics alpha.
Assertio Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 22000 shares by Mckee William of Assertio Therapeutics at 3.1384 subject to Rule 16b-3 | 09/24/2024 |
2 | Acquisition by Sam Schlessinger of 283500 shares of Assertio Therapeutics at 0.79 subject to Rule 16b-3 | 09/30/2024 |
3 | Disposition of 19404 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | 10/01/2024 |
4 | Assertio Holdings Inc Q2 2024 Earnings Call Highlights Navigating Sales Challenges and ... | 10/09/2024 |
5 | ASRT - Assertio Holdings, Inc. Latest Stock News Market Updates - StockTitan | 10/30/2024 |
6 | Insider Trading | 11/07/2024 |
7 | Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud | 11/08/2024 |
8 | Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio | 11/11/2024 |
9 | Assertio Holdings, Inc. Q3 2024 Earnings Call Transcript | 11/12/2024 |
10 | Acquisition by Ogrady Brendan P. of 11706 shares of Assertio Therapeutics at 0.85 subject to Rule 16b-3 | 11/14/2024 |
11 | Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio | 11/15/2024 |
12 | Acquisition by Heather Mason of 75000 shares of Assertio Therapeutics at 0.8 subject to Rule 16b-3 | 11/18/2024 |
13 | Assertio Holdings, Inc. Director Heather L. Mason Buys 75,000 Shares | 11/21/2024 |
14 | New Strong Buy Stocks for December 10th | 12/10/2024 |
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.